EUVIMEDEUVIMED entdecken
Crossref

Real-world clinical outcomes of intermediate-risk PAM50 (i-ROR) in HR+/HER2- early breast cancer and eligibility for adjuvant CDK4/6 inhibitors

Santiago Terán, María Illia, María Carla Quevedo, Marina López Moreno, Manuel Alva Bianchi, Laura Lema, Cristina González, Pablo Tolosa, Ainhoa Madariaga, Luis Manso, Yolanda Ruano, Lucía Parrilla und 3 weitere

Breast Cancer Research and Treatment · 2026-07 · 218 (1)

DOI: 10.1007/s10549-026-08027-y ↗

Kurz gefasst

Fachartikel in der Zeitschrift Breast Cancer Research and Treatment, online erschienen am 14.07.2026. Verfasst von Santiago Terán und 14 weiteren Autor:innen. Beteiligte Einrichtung: Medical Oncology Department, Hospital Universitario 12 de Octubre, Madrid, Spain. Hauptthemen laut MEDLINE: Breast Neoplasms, Cyclin-Dependent Kinase 4, Cyclin-Dependent Kinase 6, Protein Kinase Inhibitors. Die Arbeit nennt 34 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

INTRODUCTION: Risk-adapted strategies are central to early breast cancer (EBC) management, particularly in HR+/HER2 - disease. Prosigna/PAM50 combined with clinicopathologic factors refines prognosis, with clearer guidance at ROR extremes, while decisions in the intermediate-risk (i-ROR) group remain challenging. Although adjuvant iCDK4/6 therapy improves outcomes in high-risk patients, eligibility in i-ROR may be overlooked. This study outlines clinicopathologic features, recurrence-free survival, and iCDK4/6 eligibility in i-ROR EBC to support treatment decision-making. METHODS: We performed a retrospective analysis of 554 EBC patients who underwent PAM50 testing at Hospital Universitario 12 de Octubre (2015-2024). Clinical, pathological, diagnostic, follow-up, and recurrence data were obtained from records. Kaplan-Meier analyses estimated RFS, while multivariate logistic regression identified predictors of chemotherapy use within i-ROR. Descriptive statistics assessed eligibility for adjuvant ribociclib (NATALEE) and abemaciclib (monarchE). RESULTS: Among 212 i-ROR patients (38%), 71.7% were postmenopausal, 65.5% Luminal A and 34% Luminal B intrinsic subtypes, and 53.7% node-negative. 68.4% did not receive chemotherapy. There were 11 relapses, predominantly Luminal A (72.7%), node-negative (63.6%), and chemotherapy-naive (90.9%). RFS at 12, 36, and 60 months was 100%, 97.9%, and 96.9%. Chemotherapy use was associated with younger age (p = 0.006), node positivity (p = 0.021), and luminal B subtype (p = 0.001). CDK4/6 eligibility was 44.3% for NATALEE and 14.6% for monarchE, with 10.8% meeting both; chemotherapy use was higher in monarchE-eligible patients (41.9% vs. 31.9%). CONCLUSIONS: This real-world cohort of PAM50 i-ROR HR+/HER2 - EBC patients showed excellent prognosis (5-year RFS > 96%), yet relapses still occurred, highlighting the need for improved risk stratification and consideration of adjuvant therapies, including iCDK4/6.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Breast NeoplasmsCyclin-Dependent Kinase 4Cyclin-Dependent Kinase 6Protein Kinase InhibitorsHumansFemaleErb-b2 Receptor Tyrosine KinasesRetrospective StudiesChemotherapy, AdjuvantMiddle AgedReceptors, ProgesteroneAminopyridinesPrognosisReceptors, EstrogenAgedAdultBiomarkers, TumorNeoplasm Recurrence, LocalPurinesBenzimidazoles

Stichwörter der Autor:innen

AbemaciclibEBCEarly breast cancerHR+/HER2-NATALEEPAM50ProsignaRibociclibi-RORmonarchE

Substanzen

Erb-b2 Receptor Tyrosine KinasesCyclin-Dependent Kinase 4Cyclin-Dependent Kinase 6Receptors, ProgesteroneAminopyridinesERBB2 protein, humanProtein Kinase InhibitorsReceptors, EstrogenCDK4 protein, humanCDK6 protein, human

Autor:innen und Institutionen

  • Medical Oncology Department, Hospital Universitario 12 de Octubre, Madrid, Spain.
  • Medical Oncology Department, Hospital Universitario 12 de Octubre, Instituto de Investigación Sanitaria Hospital 12 de Octubre (imas12), Madrid, Spain.
  • Pathology Department, Hospital Universitario 12 de Octubre, Madrid, Spain.
  • Medical Oncology Department, Hospital Universitario 12 de Octubre, Madrid, Spain. rodrigo.sanchez@gruposolti.org.
  • Medical Oncology Department, Hospital Universitario 12 de Octubre, Instituto de Investigación Sanitaria Hospital 12 de Octubre (imas12), Madrid, Spain. rodrigo.sanchez@gruposolti.org.

Zitieren

APA

Terán, S., Illia, M., Quevedo, M. C., Moreno, M. L., Bianchi, M. A., Lema, L., González, C., Tolosa, P., Madariaga, A., Manso, L., Ruano, Y., Parrilla, L., Cobos, M. Á., Ciruelos, E., & Sánchez-Bayona, R. (2026). Real-world clinical outcomes of intermediate-risk PAM50 (i-ROR) in HR+/HER2- early breast cancer and eligibility for adjuvant CDK4/6 inhibitors. Breast Cancer Research and Treatment, 218(1). https://doi.org/10.1007/s10549-026-08027-y

Vancouver

Terán S, Illia M, Quevedo MC, Moreno ML, Bianchi MA, Lema L, et al. Real-world clinical outcomes of intermediate-risk PAM50 (i-ROR) in HR+/HER2- early breast cancer and eligibility for adjuvant CDK4/6 inhibitors. Breast Cancer Research and Treatment. 2026;218(1). doi:10.1007/s10549-026-08027-y

BibTeX
@article{Tern2026,
  author = {Terán, Santiago and Illia, María and Quevedo, María Carla and Moreno, Marina López and Bianchi, Manuel Alva and Lema, Laura and González, Cristina and Tolosa, Pablo and Madariaga, Ainhoa and Manso, Luis and Ruano, Yolanda and Parrilla, Lucía and Cobos, María Ángeles and Ciruelos, Eva and Sánchez-Bayona, Rodrigo},
  title = {Real-world clinical outcomes of intermediate-risk PAM50 (i-ROR) in HR+/HER2- early breast cancer and eligibility for adjuvant CDK4/6 inhibitors},
  journal = {Breast Cancer Research and Treatment},
  year = {2026},
  volume = {218},
  number = {1},
  doi = {10.1007/s10549-026-08027-y}
}
Kostenlos starten →